Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Jason D. Goldman, David Chien Lye, David S.C. Hui, +23

New England Journal of Medicine

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

Paul E. Sax, Kristine M. Erlandson, Jordan E. Lake, +14

Clinical Infectious Diseases

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

Joel E. Gallant, Adriano Lazzarin, Anthony Mills, +14

The Lancet

Treatment And PreventionAntiviral Drug DevelopmentClinical TrialsAntiviral TherapyVirology +7

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

Edwin DeJesus, Jürgen K. Rockstroh, Keith Henry, +9

The Lancet

Hiv/aids CounsellingTreatment And PreventionMedicineAntiviral Drug DevelopmentClinical Trials +10

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment

Anton Pozniak, José Ramón Arribas, Joseph Gathe, +16

JAIDS Journal of Acquired Immune Deficiency Syndromes

Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

David A. Wohl, Yazdan Yazdanpanah, Axel Baumgarten, +11

The Lancet HIV

Week 96Treatment And PreventionAntiviral Drug DevelopmentAntiviral TherapyVirology +7

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

Hans‐Jürgen Stellbrink, José Ramón Arribas, Jeffrey L. Stephens, +10

The Lancet HIV

Week 96Antiviral Drug DevelopmentAntiviral TherapyVirologyPharmacotherapy +6

A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection

Jürgen K. Rockstroh, Edwin DeJesus, Keith Henry, +9

JAIDS Journal of Acquired Immune Deficiency Syndromes

Week 48PharmacotherapyAntiviral DrugLogistic AnalysisAdverse Drug Reaction +16

Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials

Kristine M. Erlandson, Christoph C Carter, Kathleen Melbourne, +15

Clinical Infectious Diseases

Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1–Infected Adults

Joel E. Gallant, Melanie Thompson, Edwin DeJesus, +7

JAIDS Journal of Acquired Immune Deficiency Syndromes